Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Short term Debt (2016 - 2022)

Historic Short term Debt for Aptevo Therapeutics (APVO) over the last 8 years, with Q4 2022 value amounting to $2.0 million.

  • Aptevo Therapeutics' Short term Debt fell 8285.76% to $2.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $2.0 million, marking a year-over-year decrease of 8285.76%. This contributed to the annual value of $2.0 million for FY2022, which is 8285.76% down from last year.
  • Aptevo Therapeutics' Short term Debt amounted to $2.0 million in Q4 2022, which was down 8285.76% from $2.0 million recorded in Q3 2022.
  • In the past 5 years, Aptevo Therapeutics' Short term Debt registered a high of $19.9 million during Q4 2019, and its lowest value of $2.0 million during Q1 2022.
  • Its 5-year average for Short term Debt is $8.1 million, with a median of $5.3 million in 2018.
  • Its Short term Debt has fluctuated over the past 5 years, first surged by 13334.0% in 2021, then plummeted by 8285.76% in 2022.
  • Aptevo Therapeutics' Short term Debt (Quarter) stood at $4.2 million in 2018, then skyrocketed by 376.67% to $19.9 million in 2019, then crashed by 74.83% to $5.0 million in 2020, then surged by 133.34% to $11.7 million in 2021, then crashed by 82.86% to $2.0 million in 2022.
  • Its Short term Debt was $2.0 million in Q4 2022, compared to $2.0 million in Q3 2022 and $2.0 million in Q2 2022.